<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00790244</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT number 2007-001152-39</org_study_id>
    <nct_id>NCT00790244</nct_id>
  </id_info>
  <brief_title>A Scandinavian Sarcoma Group Protocol for Patients With High-risk Soft Tissue Sarcoma of the Extremities and Trunk Wall</brief_title>
  <acronym>SSGXX</acronym>
  <official_title>A Scandinavian Sarcoma Group Treatment Protocol for Adult Patients With Non-metastatic High-risk Soft Tissue Sarcoma of the Extremities and Trunk Wall</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Scandinavian Sarcoma Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SSG XX is a phase II trial for high-risk soft tissue sarcomas (STS) of the extremities and
      trunk wall. Prognostic factors (histopathological markers) are used to identify high-risk
      tumors. SSG XX will evaluate chemo- and radiotherapy given adjuvantly to these patients. In a
      specified group of patients also preoperatively given therapy will be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SSG XX, the third adjuvant STS protocol by SSG, is a phase II non-randomized trial in
      patients with high risk to develop metastases. SSG XX is based on a previous SSG trial (SSG
      XIII) regarding use of prognostic markers to identify high-risk tumors and include very
      similar chemo- and radiotherapy treatment schedules compared to SSG XIII, but the new
      protocol also includes a treatment arm with preoperative chemo- and radiotherapy for patients
      with an obvious risk for intralesional surgery initially.

      Patients: In this new adjuvant protocol SSG adopts an inclusion decision algorithm based on
      the following criteria: 1.vascular invasion or 2. presence of at least two of the risk
      factors: tumor size =&gt;8 cm, necrosis or infiltrative growth(all defined microscopically by
      the pathologist. The system was developed retrospectively by evaluation of 434 primary
      histologically high grade (III-IV) STS from the SSG registry, and was later validated in a
      series of 175 patients in which patients with a high risk for metastases (&gt;40 %) and low risk
      (&lt;15 %) were separated (Engellau J et al.Eur J Ca 2007 43: 1927-34). Inclusion criteria: age
      ≥ 18 y and &lt;75 y. Primary end point is metastasis-free survival. Local recurrence and
      toxicity will also be studied.

      Treatment: Six cycles of doxorubicin 60mg/m2 and ifosfamide 6g/m2 will be given adjuvantly
      (to patients ≥ 70y: 50mg/m2 and 5g/m2 ). Dependent on surgical resection margins, 36Gy or
      45Gy (1,8Gy per fraction, two fractions daily) will be given interpolated with chemotherapy.

      Conclusion: SSG XX will evaluate chemo-and radiotherapy given adjuvantly to patients with STS
      and high risk for metastases (arm A). In a specified group of patients also preoperatively
      given therapy will be studied(arm B). Other sarcoma centers are invited to participate in the
      study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metastases-free survival</measure>
    <time_frame>time frame from start of treatment until the events metastases or death of any cause</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of local recurrence,overall survival,acute and late toxicity,secondary malignancies</measure>
    <time_frame>for ten years from start of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Soft Tissue Sarcoma</condition>
  <condition>Non Metastatic Disease</condition>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&lt;70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and 4.
(&gt;=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&lt;70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 45Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and 4.
(&gt;=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&lt;70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 2 and 3.
(&gt;=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&lt;70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle (&gt;=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin , ifosfamide</intervention_name>
    <description>doxorubicin 60mg/m2+ifosfamide 6g/m2 every third week</description>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Doxorubicin</other_name>
    <other_name>Holoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin, ifosfamide</intervention_name>
    <description>Doxorubicin and Ifosfamide given every three weeks, totally 6 courses.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Doxorubicin</other_name>
    <other_name>Holoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin, ifosfamide</intervention_name>
    <description>&lt;70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and four.
(&gt;=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Doxorubicin</other_name>
    <other_name>Holoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin, ifosfamide</intervention_name>
    <description>&lt;70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 2 and 3.
(&gt;=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Doxorubicin</other_name>
    <other_name>Holoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Group A: Histological high-grade malignancy soft tissue sarcomas of the extremity and trunk
        wall.

        Patients fulfilling the high-risk criteria defined above (see detailed description) Group
        B: Patients with histological high-grade malignancy soft tissue sarcomas of the extremity
        and trunk wall for whom surgery carries an obvious risk of intralesional margin

        Other inclusion criteria for therapy group A and group B

          -  Age ≥ 18 y and ≤ 75 y

          -  WHO grade 0-1

          -  Adequate cardiac function (LVEF ≥ 50%)

          -  Normal GFR (clearance)

          -  Adequate haematologic and liver function

          -  All histotypes except those listed below

        Exclusion Criteria:

        The following histological types:

          -  Extraskeletal osteosarcoma and - chondrosarcoma, Ewing/PNET, rhabdomyosarcoma,
             Kaposi´s sarcoma, malignant mesenchymoma, clear cell sarcoma, alveolar soft part
             sarcoma, epithelioid sarcoma

          -  Radiation induced sarcoma

          -  No previous anthracycline treatment

          -  Less than 5 years free of another primary malignancy

          -  More than 12 weeks have elapsed since primary surgery (Group A)

          -  More than 4 weeks from diagnostic biopsy to start of chemotherapy (Group B)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirsten Sundby Hall, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>c/o: Scandinavian Sarcoma Group, Southern Swedish Regional Tumor Registry, Lund University Hospital, SE-221 85 Lund</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kirsten Sundby Hall, MD, PhD</last_name>
    <phone>+4722934000</phone>
    <email>k.s.hall@klinmed.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mikael Eriksson, MD,PhD</last_name>
    <phone>+4646177507</phone>
    <email>mikael.eriksson@onk.lu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Scandinavian Sarcoma Group Secretariat</name>
      <address>
        <city>Lund University Hospital</city>
        <state>Lund</state>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Sundby Hall, MD,PhD</last_name>
      <phone>+4722934000</phone>
      <email>k.s.hall@klinmed.uio.no</email>
    </contact>
    <contact_backup>
      <last_name>Mikael Eriksson, MD,PhD</last_name>
      <phone>+4646 177507</phone>
      <email>mikael.eriksson@onk.lu.se</email>
    </contact_backup>
    <investigator>
      <last_name>Kirsten Sundby Hall, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scandinavian Sarcoma Group centers</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Sundby Hall, MD, PhD</last_name>
      <phone>+4722934000</phone>
      <email>k.s.hall@klinmed.uio.no</email>
    </contact>
    <contact_backup>
      <last_name>Mikael Eriksson, MD,PhD</last_name>
      <phone>+4646177507</phone>
      <email>mikael.eriksson@onk.lu.se</email>
    </contact_backup>
    <investigator>
      <last_name>Kirsten Sundby Hall, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mikael Eriksson, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.ssg-org.net</url>
    <description>Scandinavian Sarcoma Group</description>
  </link>
  <reference>
    <citation>Engellau J, Samuelsson V, Anderson H, Bjerkehagen B, Rissler P, Sundby-Hall K, Rydholm A. Identification of low-risk tumours in histological high-grade soft tissue sarcomas. Eur J Cancer. 2007 Sep;43(13):1927-34. Epub 2007 Jul 12.</citation>
    <PMID>17627813</PMID>
  </reference>
  <reference>
    <citation>Engellau J, Bendahl PO, Persson A, Domanski HA, Akerman M, Gustafson P, Alvegård TA, Nilbert M, Rydholm A. Improved prognostication in soft tissue sarcoma: independent information from vascular invasion, necrosis, growth pattern, and immunostaining using whole-tumor sections and tissue microarrays. Hum Pathol. 2005 Sep;36(9):994-1002.</citation>
    <PMID>16153463</PMID>
  </reference>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2008</study_first_submitted>
  <study_first_submitted_qc>November 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <last_update_submitted>July 3, 2011</last_update_submitted>
  <last_update_submitted_qc>July 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Kirsten Sundby Hall</name_title>
    <organization>Rikshospitalet-Radiumhospitalet HF</organization>
  </responsible_party>
  <keyword>Soft-tissue sarcomas</keyword>
  <keyword>prognostic factors</keyword>
  <keyword>adjuvant</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>metastases-free survival</keyword>
  <keyword>toxicity</keyword>
  <keyword>High malignancy grade</keyword>
  <keyword>High-risk for metastases</keyword>
  <keyword>Adult</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

